Phase I Pharmacokinetics Study of Oral Administration of Esperavir® (INN: Molnupiravir) (LLC "PROMOMED RUS", Russia)
Introduction. The pandemic of the new coronavirus infection COVID-19 (Coronavirus Disease 2019) was caused by a single-stranded RNA virus SARS-CoV-2 (Severe acute respiratory syndrome-related coronavirus 2). Molnupiravir is an antiviral drug with activity against RNA viruses including SARS-CoV-2. Mo...
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Russo |
| Udgivet: |
LLC Center of Pharmaceutical Analytics (LLC «CPHA»)
2024-03-01
|
| Serier: | Разработка и регистрация лекарственных средств |
| Fag: | |
| Online adgang: | https://www.pharmjournal.ru/jour/article/view/1754 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|